Appia Bio

A pipeline of novel therapeutic potential for cancer patients

Cell type

Program

Discovery

Preclinical

IND-enabling

Phase 1

Pivotal

Partners

CAR-NKT

CD19/CD20

AML Target

Multiple Myeloma Dual Target

Solid Tumors

CAR-γδ T

Autoimmune

Technology that spans the promise of both NK and T cell therapies by harnessing the power of rare, potent, cancer-fighting invariant T cells

Appia Bio's Technology Lab

If you're passionate about making waves in cell therapy, we'd love to hear from you

Join our teamContact Us